Anti-IL17 antibody Secukinumab therapy is associated with ossification in giant cell tumor of bone: a case report of pathologic similarities and therapeutic potential similar to Denosumab

Andrew Chandler, Meredith K. Bartelstein, Tomohiro Fujiwara, Cristina R. Antonescu, John H. Healey, Max Vaynrub

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background: Giant cell tumor of bone is a benign, locally aggressive neoplasm. Surgical resection is the preferred treatment method. However, for cases in which resection poses an increased risk to the patient, denosumab (anti-RANKL monoclonal antibody) is considered. Secukinumab is an anti-IL-17 antibody that is used in psoriatic arthritis to reduce bone resorption and articular damage. Case presentation: One case of giant cell tumor of bone (GCTB) in a patient treated with secukinumab for psoriatic arthritis demonstrated findings significant for intra-lesional calcifications. Histologic examination showed ossification, new bone formation, and remodeling. A paucity of osteoclast type giant cells was noted. Real-time quantitative polymerase-chain-reaction (qRT-PCR) analysis revealed decreased osteoclast function compared to treatment-naive GCTB. Conclusions: Secukinumab may play a role in bone remodeling for GCTB. Radiologists, surgeons, and pathologists should be aware of this interaction, which can cause lesional ossification. Further research is required to define the therapeutic potential of this drug for GCTB and osteolytic disease.

Original languageEnglish
Article number320
JournalBMC Musculoskeletal Disorders
Volume22
Issue number1
DOIs
Publication statusPublished - Dec 2021
Externally publishedYes

Keywords

  • Case report
  • Denosumab
  • EGFR
  • GCTB
  • IL-17
  • Osteoprogeterin
  • RANKL
  • Secukinumab

ASJC Scopus subject areas

  • Rheumatology
  • Orthopedics and Sports Medicine

Fingerprint

Dive into the research topics of 'Anti-IL17 antibody Secukinumab therapy is associated with ossification in giant cell tumor of bone: a case report of pathologic similarities and therapeutic potential similar to Denosumab'. Together they form a unique fingerprint.

Cite this